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Influence of tumour physico-chemical conditions on interleukin-2-stimulated
lymphocyte proliferation
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Summary The proliferative response of murine lymphocytes to interleukin-2 (IL-2) was examined under
physico-chemical conditions present in solid tumours, namely low oxygen and glucose concentrations and
acidic pH. Lymphocytes were cultured for four days in 30Uml-' IL-2 to simulate serum IL-2 concentrations
attainable with high-dose systemic IL-2 therapy. Lymphocyte proliferation was significantly (P<0.05) reduced
by low oxygen concentrations (both anoxia [0%02] and hypoxia [10%, low glucose (6mgdl-1), or acidic pH
(6.7 or 6.4). Moderate glucose concentration (32mgdlP'), or neutral pH (7.0) did not impair proliferation.
This study indicates that impairment of lymphocyte proliferation by tumour physico-chemical conditions may
be a factor in the relatively poor success rate of IL-2/LAK cell immunotherapy.
Interleukin-2 (IL-2) provides a second signal for proliferation
and differentiation of activated T lymphocytes (Ruscetti &
Gallo, 1981; Bubenick, 1990). Clinical trials with
lymphokine-activated killer (LAK) cells and IL-2 have been
disappointing, with clinical response observed in only a few
tumour systems, notably malignant melanoma and renal cell
carcinoma. Even with these tumours, complete remissions
have occurred in only 10-20% of patients (Rosenberg et al.,
1985, 1987). The disparity between in vitro and in vivo results
may be due in part to poor localisation of LAK cells to solid
tumours (Lotze et al., 1980). Tumour remissions have been
reported with systemic IL-2 treatment alone (Lotze et al.,
1986; Louie et al., 1989; Oliver et al., 1989; Sosman et al.,
1990). The anti-tumour effects of IL-2 are believed to be due
to activation and proliferation of tumour-infiltrating lym-
phocytes (TIL) (Ettinghausen et al., 1985; Eggermont et al.,
1987), although lymphocytes activated by IL-2 at distant sites
may traffic to tumours as well. The tumour microenviron-
ment differs markedly from that within non-neoplastic tis-
sues, due primarily to insufficient vascular supply and
decreased tumour blood flow (Vaupel et al., 1989). Among
the physico-chemical conditions which comprise the tumour
microenvironment are low oxygen and glucose concentra-
tions, as well as acidic pH due to insufficient removal of
lactic acid (Gullino et al., 1964; Vaupel et al., 1981). As the
distribution of nutrients and pH is frequently heterogeneous
within tumours (Vaupel et al., 1981, 1989), TIL may be
exposed to a range of physico-chemical conditions depending
upon their location. TIL are generally observed in the
tumour periphery and stroma, but may also be more cent-
rally located in direct contact with neoplastic cells (Dvorak et
al., 1981; Bhan & DesMarais, 1983; Vaage & Pepin, 1985).
The purpose of the present study was to determine whether
the range of physico-chemical conditions reported in solid




Male and female BALB/c mice from 2-6 months of age were
used in these experiments. The mice were originally obtained
from the Cancer Research Laboratory, University of Califor-
nia at Berkeley, and were maintained in our animal facility
by brother-sister mating.
In vitro tymphocyte proliferation
Mice were sacrificed by cervical dislocation, and their spleens
were dispersed by pushing through a 40 mesh wire screen.
The cells were allowed to adhere for 45min on 100mm tissue
culture dishes. Nonadherent cells were collected and eryth-
rocytes were lysed with NH4Cl (0.14M in Tris base), followed
by two washes with Hanks' balanced salt solution (HBSS,
Gibco Laboratories, Grand Island, NY). Lymphocytes were
resuspended to 106 live cellsml1' in appropriate media (see
below) together with 30Uml-1 of recombinant human IL-2
(Cetus Corporation, Richmond, CA) and 4 x 10-5M 2-
mercaptoethanol (2-ME). The specific activity of this IL-2
preparation was 3 x 106UMml-'. This concentration of IL-2
was chosen because 30 U ml- IL-2 is reported to be
achievable in serum during systemic treatment (intravenous
infusion over 6h) with IL-2 at 106Um-2 (Mertelsmann &
Welte, 1986). For proliferation assays in varying pH or
glucose, 2 x 105 cells (200gl) were dispensed per well in a
96-well round-bottom microtiter plate. For evaluation of
lymphocyte proliferation in hypoxic conditions alone, cells
were dispensed in ml volumes into 6 x 50mm borosilicate
glass test tubes. All conditions were evaluated in triplicate or
quadruplicate in each assay, and each experiment was per-
formed on at least three separate occasions.
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Production oftumour-like physico-chemical conditions
Low oxygen concentrations Lymphocytes were resuspended
to 106ml1' in RPMI-1640 (Gibco) supplemented with 10%
foetal calf serum (FCS), lOOuml'1 penicillin, 100pgmlh'
streptomycin, 10% NCTC-109 (Whittaker M.A. Bioproducts,
Walkersville, MD), 2mM L-glutamine, O.1mm non-essential
amino acids, 1mm sodium pyruvate, 1gm 500ml NaHCO3,
and 20mM Hepes buffer. (Hereafter, this medium will be
referred to as SRPMI). The procedure for production of
hypoxia has been described previously (Loeffler et al., 1990).
Briefly, 1 ml of cells was dispensed into 6 x 50mm glass test
tubes as described above; the tubes were placed in a 96 well
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microtiter plate, inside a plexi-glass chamber connected via
Tygon tubing to a tank containing 95% N2/5% CO2 (anoxia)
or 1% 02/94% N2/5% CO2 (hypoxia). The chamber was
placed within a 37°C incubator. Oxygen concentrations were
measured via an MI-730 Micro-Oxygen electrode (Microelec-
trodes, Inc., Londonderry, NH) and determined to be 0.2%
and 1.3% when cells were gassed with 0% 02 and 1% 02,
respectively. Aerobic controls were incubated at 37°C in
room air/5% CO2. Lymphocytes were cultured in IL-2 for
72h, then 3H-thymidine (0.5pCi/tube) was added. (Tubes
were briefly removed from the hypoxia chamber in order to
add the radioisotope). Eighteen h later, cells were harvested
with a cell harvester, and 3H-thymidine incorporation into
cells was determined with a beta counter. Addition of 3H-
thymidine and harvesting of lymphocytes was similar for the
other proliferation assays described below.
Low glucose Glucose-free Dulbecco's Minimal Essential
Medium (DME, Sigma Chemical Company, St Louis, MO)
was supplemented as described above for RPMI-1640, except
that pyruvic acid and NCTC-109 were omitted, and the
concentration of FCS was reduced to 2%. The glucose con-
centration in this medium (as measured with the Glucose
HK-10 Test Kit from Sigma) was approximately 6mgdl1'.
Glucose (alpha-D(+)glucose, Sigma) was added to yield a
final concentration of either 32mgdl-' or 125mgdl-'. IL-2-
stimulated lymphocyte proliferation in varying glucose con-
centrations was evaluated by resuspending lymphocytes to
106ml`' in each of the three media, together with IL-2 and
2-ME as described above. 2 x I05 cells (200fd)/well were
dispensed into 96 well round-bottom microtiter plates. Plates
were centrifuged daily and half of the medium was replaced
with new medium in order to compensate for utilisation of
glucose by the actively proliferating cells.
Acidic pH SRPMI was adjusted to pH 7.4, 7.0, 6.7, or 6.4
by addition of 1NHC1 or 1NNaOH, then sterile filtered.
Lymphocytes were resuspended in IL-2 and 2-ME and
dispensed in microtiter plates as described above. One-half of
the medium in each well was replaced each day with fresh
IL-2-containing medium (adjusted to proper pH immediately
before use) in order to minimise pH variations. Values for
pH were found to fluctuate by 0.1-0.2 pH units during the
assay.
Statistical analysis Data from typical experiments under
each set of physical conditions were chosen for statistical
analysis. For assays in which pH or glucose were varied, the
one-way analysis of variance (ANOVA) was used to deter-
mine whether treatment effects were present for pH or
glucose levels. Where ANOVA indicated the presence of
significant treatment differences, pairwise differences were
evaluated by Tukey's Multiple Range Procedure (Zar, 1984).
For assays of lymphocyte proliferation in varying 02 concen-
trations, Student's t-test was used to compare pairwise
differences.
Results
Lymphocyte proliferation in low oxygen concentrations
IL-2-stimulated lymphocyte proliferation under hypoxic (1%
02) and anoxic (0% 02) conditions was compared with pro-
liferation in room air (20% 02)- Proliferation was similar in
both 1% 02 and 0% 02, and for both conditions was
significantly less than in room air (P<.0001 and P=.0049,
respectively) Figures la-b).
Lymphocyteproliferation in low glucose concentrations
Lymphocyte proliferation in 6mgdl ' and 32mgdl-l glucose
concentrations was compared with proliferation in normal
serum glucose concentration (125mgdl-'). Proliferation in
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Figure 1 IL-2-stimulated lymphocyte proliferation in 1%02 (a)
and 0%02 (b) compared to proliferation in room air (20%02).
Lymphocyte proliferation was significantly decreased in both con-
ditions compared to room air (P<.0001 and P = 0049, respec-
tively).
glucose (P = .01); proliferation was not significantly different
between 32mgdl1' and 125mgdl1l glucose (Figure 2).
Lymphocyteproliferation in acidicpH
Lymphocyte proliferation in pH 7.0, 6.7, and 6.4 was com-
pared to that at pH 7.4. Proliferation at pH 6.4 and 6.7 was
significantly decreased, whereas proliferation was increased at
pH 7.0 (P = .05 with Tukey's test) (Figure 3).
Discussion
The effectiveness of IL-2 therapy presumably depends upon a
variety of factors, including toxicity, concentration of IL-2
delivered to the tumour, extent of lymphocytic infiltration,
response of TIL to IL-2, and sensitivity of tumour cells to
cytotoxic effects of the activated TIL. The present study
examined IL-2-stimulated lymphocyte proliferation under the
range of physico-chemical conditions reported for experi-
mental tumours in laboratory animals. The actual tumour
microenvironment is clearly more complex than this in vitro
model, with other factors (including suppressor cells and
soluble immunosuppressor factors) influencing TIL respon-
siveness as well. Splenic lymphocytes rather than TIL were
employed in these experiments because the IL-2 receptor is
not well expressed on TIL, and in vitro proliferative response
of TIL to I1-2 is poor (Miescher et al., 1986). It may be that
TIL IL-2 receptor expression is down-regulated in part by
tumour physico-chemical conditions, although this was not
examined in the present study.
Oxygen concentrations in the range of radiobiological
hypoxia (1% 02) as well as anoxia (0% 02) significantly
reduced lymphocyte proliferation, as did extremely low
glucose concentration (6mgdl-') and acidic pH (6.4 and 6.7).
However, more moderate conditions (either 32mgdl-'
glucose or pH 7.0) did not decrease lymphocyte respon-
siveness to IL-2; in fact, lymphocyte proliferation at pH 7.0
was significantly increased relative to pH 7.4. These results
suggest that the influence of tumour physico-chemical condi-
tions on lymphocyte proliferation depends upon the severity
of these conditions within the tumour, as well as the location
of the TIL. Lymphocytes situated in the tumour periphery
are not likely to be exposed to the extreme conditions which









Figure 2 IL-2-stimulated lymphocyte proliferation in low glucose
concentrations. Lymphocyte proliferation was significantly
reduced in 6 mg dl-' glucose compared to 125 mg dl-' glucose
(P = .01).
of more centrally located TIL may be down-regulated. How-
ever, tumour cells in hypoxic areas are more resistant to
radiotherapy and some forms of chemotherapy than their
well-oxygenated counterparts (Gray et al., 1953; Bush et al.,
1978; Hill & Stanley, 1975; Tannock, 1982), and it is these
cells which must be targeted if immunotherapy is to be a
useful addition to standard therapy protocols. Inhibition of
lymphocyte proliferation under tumour physico-chemical
conditions is not specific for this cell type, as these same
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Figure 3 IL-2-stimulated lymphocyte proliferation in acidic pH.
Proliferation was decreased in pH 6.4 and 6.7 in comparison with
proliferation in pH 7.4 (P = .05 with Tukey's test for both condi-
tions); proliferation was significantly increased at pH 7.0 com-
pared to pH 7.4.
central areas of tumours (Rotin et al., 1986; Tannock &
Kopelyan, 1986). Our results suggest that inhibition of IL-2-
stimulated lymphocyte proliferation by tumour physico-
chemical conditions may be a factor in the relatively poor
success rate of IL-2/LAK cell immunotherapy. Short-term
improvement of physical conditions within tumours during
administration of IL-2, such as increasing tumour P02 by
Fluosol-DA plus carbogen (Fischer et al., 1986), should be
examined in animal models to determine if TIL response to
IL-2 may be improved. The potential benefit of increasing
TIL responsiveness by alteration of the tumour microen-
vironment must be evaluated against the possibility of con-
comitant increase in tumour cell proliferation under more
normal physico-chemical conditions.
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